Source: Dana-Farber Cancer Institute From: Redington Newsdesk Dana-Farber Cancer Institute scientists say they have identified factors that predict improved response and survival in patients with head and neck cancers treated with checkpoint inhibitor immunotherapy. Two immunotherapy agents known as checkpoint inhibitors have been approved to treat patients whose disease is resistant to standard platinum-based chemotherapy. However, only a minority of …